Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active. Treatment with MMC is usually reserved for second- or third-line treatment. We have given MMC as second- or third-line treatment to 59 patients. Fifty-six patients were evaluable for response. No complete and only 3 partial responses were observed for an overall response rate of 5%. The median time to progression was 2 months and median survival time was 6 months. In this retrospective study MMC is demonstrated to be inactive in third-line chemotherapy.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D013997:Time Factors
D008937:Mitomycins; D016685:Mitomycin